Send to

Choose Destination
Bioorg Med Chem Lett. 2013 May 1;23(9):2480-5. doi: 10.1016/j.bmcl.2013.03.034. Epub 2013 Mar 16.

Inhibitors of the p53/hdm2 protein-protein interaction-path to the clinic.

Author information

Oncology Drug Discovery and Preclinical Development, Sanofi, 13 Quai Jules Guesde, 94400 Vitry-sur-Seine, France.


A growing number of the elements identified in intracellular signaling events that affect cell growth and transformation are proteins that physically interact with each other via domains or specifically recognized amino acid sequences. Some of these intracellular protein-protein interactions are attractive targets for anticancer targeted therapy, but progress in this field has been compromised by the paucity of compounds with suitable biological profiles and pharmacological properties. This Letter covers salient achievements in the identification and development of inhibitors of the p53-hdm2 protein-protein interaction, and highlights different screening techniques and structure-based design approaches that may be brought to bear on the discovery and development of inhibitors of other therapeutically relevant intracellular protein-protein interactions.

[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center